TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 2807927
Drug: Urea-containing cream
Approvals — FDA: no, EMA: no, PMDA: no
Description: Urea-containing cream
Study: 28349493
Drug: Nigella sativa
Normalized name: NIGELLA SATIVA SEED
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nigella sativa seeds (5 g daily throughout treatment)
Study: 25956072
Drug: tiotropium +
Approvals — FDA: no, EMA: no, PMDA: no
Description: tiotropium + olodaterol FDC 5/5 μg
Study: 21593490
Drug: B vitamins
Normalized name: B-50 Hi Potency B Vitamins
Approvals — FDA: no, EMA: no, PMDA: no
Description: B vitamins (5-methyltetrahydrofolate 0.56 mg, vitamins B-6 3 mg, B-12 0.02 mg) and omega-3 fatty acids (eicosapentaenoic and docosahexaenoic acids 600 mg)
Study: 19912346
Drug: OnabotulinumtoxinA (BOTOX),
Approvals — FDA: no, EMA: no, PMDA: no
Description: OnabotulinumtoxinA (BOTOX), maximum 200 units at baseline and month 3, plus oral placebo
Study: 19912346
Drug: Topiramate (TOPAMAX),
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topiramate (TOPAMAX), 4-week titration to 100 mg/day with option for additional 4-week titration to 200 mg/day, plus placebo saline injections
Study: 9132744
Drug: Flunisolide (FLUN)
Normalized name: Flunisolide
DrugBank: Flunisolide acetate (DB14662)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Flunisolide (FLUN) metered dose inhaler 2 x 500 micrograms/d
Study: 3531315
Drug: sucralfate 2
Normalized name: sucralfate 200 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: sucralfate 2 g 2 i.d. (on waking and at bedtime)
Study: 3531315
Drug: sucralfate 1
Normalized name: sucralfate 1 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: sucralfate 1 g 4 i.d. (1/2 h before meals and at bedtime)
Study: 29330940
Drug: Intralesional steroid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intralesional steroid injection
Study: 24211400
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of trabectedin plus pegylated liposomal doxorubicin (PLD)
Study: 23164667
Drug: Standard procedure
Normalized name: HOMOSALATE 60 mg in 1 mL / OCTOCRYLENE 30 mg in 1 mL / ZINC OXIDE 80 mg in 1 mL TOPICAL STICK [Standard Procedure Lip Balm SPF 50]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard procedure (general anesthesia with postoperative morphine treatment)
Study: 16085588
Drug: F +
Normalized name: Estroven Menopause Relief + Mood Caplet
Approvals — FDA: no, EMA: no, PMDA: no
Description: F + 0 protocol (immediate administration of radiopharmaceutical after furosemide)
Study: 16085588
Drug: F -
Normalized name: F - Fluorine
Approvals — FDA: no, EMA: no, PMDA: no
Description: F - 15 protocol (radiopharmaceutical administered 15 min after furosemide)
Study: 7546992
Drug: Metoprolol 50-100
Normalized name: hydrochlorothiazide
DrugBank: Hydrochlorothiazide (DB00999)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Metoprolol 50-100 mg twice daily
Study: 7546992
Drug: Xamoterol 100-200
Normalized name: Xamoterol
DrugBank: Xamoterol (DB13781)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Xamoterol 100-200 mg twice daily
Study: 6920252
Drug: Dexamethasone (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexamethasone (2 mg/dose) administered 72, 48, and 24 hours before delivery
Study: 6920252
Drug: Dexamethasone (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexamethasone (2 mg/dose)
Study: 31652857
Drug: Exergaming intervention
Normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Exergaming intervention (once‐weekly 50‐minute sessions during recess for 8 months)
Study: 28910200
Drug: 12-g β-alanine
Normalized name: Alanine
DrugBank: Alanine (DB00160)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 12-g β-alanine (12G)
Study: 28910200
Drug: 6-g β-alanine
Normalized name: alanine 6.6 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 6-g β-alanine (6G)
Study: 23494053
Drug: 5,000 IU
Normalized name: bleopmycin 15,000 IU Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5,000 IU unfractionated heparin (UFH)
Study: 23494053
Drug: 2,500 IU
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2,500 IU low-molecular-weight heparin (LMWH, dalteparin)
Study: 23494053
Drug: Both heparin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both heparin types
Study: 19565734
Drug: Acupuncture combined
Normalized name: combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acupuncture combined with magnetic therapy
Study: 19565734
Drug: Simple magnetic
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Simple magnetic therapy (Control)
Study: 18006969
Drug: Prostate biopsies
Normalized name: Sus scrofa prostate preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prostate biopsies for participants with a prostate specific antigen level of 1.5 ng/ml or more
Study: 15994145
Drug: Tamoxifen (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tamoxifen (20 mg/d orally)
Study: 9704781
Drug: Epidural bupivacaine,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Epidural bupivacaine, 0.25%, 13 mL
Study: 8943593
Drug: Morphine sulphate
Normalized name: Morphine sulphate
DrugBank: Morphine (DB00295)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Morphine sulphate 10 mg
Study: 8582463
Drug: Morphine sulphate
Normalized name: Morphine sulphate
DrugBank: Morphine (DB00295)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Morphine sulphate 15 mg
Study: 8582463
Drug: Lorazepam 1
Normalized name: lorazepam 1 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lorazepam 1 mg (positive control)
Study: 350248
Drug: Intravenous labetalol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous labetalol (fast injection)
Study: 350248
Drug: Intravenous labetalol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous labetalol (slow injection)
Study: 350248
Drug: Other vasodilator
Normalized name: Other vasodilators used in cardiac diseases
Approvals — FDA: no, EMA: no, PMDA: no
Description: Other vasodilator hypotensive drugs
Study: 27310606
Drug: Multisensory stimulation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multisensory stimulation therapy (6 sessions of 30 minutes each)
Study: 15583582
Drug: Oral administration
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral administration of Polypodium leucotomos (PL) 7.5 mg/kg
Study: 9164223
Drug: Gemcitabine (GEM)
DrugBank: Gemcitabine (DB00441)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Gemcitabine (GEM) 1,250 mg/m2 as a 30‐minute intravenous infusion on days 1, 8, and 15 of each 28‐day cycle
Study: 9164223
Drug: Cisplatin (80
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cisplatin (80 mg/m2 on day 1) and Etoposide (80 mg/m2 on days 1, 2, and 3 of each 28‐day cycle)
Study: 7524907
Drug: G‐CSF (filgrastim
Approvals — FDA: no, EMA: no, PMDA: no
Description: G‐CSF (filgrastim 5 micrograms/kg/day) administered prior to and after PBSC reinjection
Study: 7524907
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no G‐CSF prior to leukaphereses or after high‐dose therapy)
Study: 7524907
Drug: Both groups
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both groups (G‐CSF and control)
Study: 3109764
Drug: Intravenous tissue
Normalized name: allogeneic processed thymus tissue Drug Implant [Rethymic]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous tissue plasminogen activator (rt-PA) 80 mg (40 mg, 20 mg, and 20 mg in successive hours)
Study: 3109764
Drug: Intravenous streptokinase
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous streptokinase (SK) 1.5 million units over 1 hr
Study: 2959716
Drug: Intravenous tissue
Normalized name: allogeneic processed thymus tissue Drug Implant [Rethymic]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous tissue plasminogen activator (rt-PA)
Study: 2868337
Drug: Intravenous streptokinase
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous streptokinase (SK)
Study: 26291080
Drug: 500 mg
Normalized name: bran 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 500 mg E-52862
Study: 26291080
Drug: 600 mg
Normalized name: mesna 600 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 600 mg E-52862
Study: 26291080
Drug: 800 mg
Normalized name: bran 800 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 800 mg E-52862
Study: 20628233
Drug: 4 mg
Normalized name: lutein 4 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4 mg zoledronic acid infusions (monthly, bi-monthly, tri-monthly, or semestral)
Study: 12728462
Drug: Iodine restriction
Normalized name: Iodine
DrugBank: Iodine (DB05382)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Iodine restriction (less than 100 micro g/day)
Study: 10915728
Drug: Interferon beta
Normalized name: Interferon beta
DrugBank: Human interferon beta (DB14999)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Interferon beta (6 million units, twice a week for 36 months)
Study: 10915728
Drug: No IFN
Approvals — FDA: no, EMA: no, PMDA: no
Description: No IFN therapy (control group)
Study: 8725871
Drug: Ergoset (1.6-2.4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ergoset (1.6-2.4 mg/day)
Study: 1483671
Drug: Cimetidine 400
Normalized name: cimetidine 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cimetidine 400 mg in saline solution
Study: 1483671
Drug: Ranitidine 150
Normalized name: ranitidine 150 MG
DrugBank: Ranitidine (DB00863)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ranitidine 150 mg in saline solution
Study: 30473097
Drug: LY3298176 10
Approvals — FDA: no, EMA: no, PMDA: no
Description: LY3298176 10 mg
Study: 30473097
Drug: LY3298176 15
Approvals — FDA: no, EMA: no, PMDA: no
Description: LY3298176 15 mg
Study: 30473097
Drug: LY3298176 1.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: LY3298176 1.5 mg
Study: 30473097
Drug: LY3298176 4.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: LY3298176 4.5 mg
Study: 27225316
Drug: n‐3 LCPUFA‐rich
Approvals — FDA: no, EMA: no, PMDA: no
Description: n‐3 LCPUFA‐rich fish oil capsules (800 mg/d DHA and 100 mg/d EPA)
Study: 24316517
Drug: Vancomycin 500
Normalized name: vancomycin 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vancomycin 500 mg t.i.d. for 7 days
Study: 24316517
Drug: Amoxicillin 500
Normalized name: amoxicillin 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amoxicillin 500 mg t.i.d. for 7 days
Study: 23880333
Drug: Cognitive-behavioral therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive-behavioral therapy (CBT) group
Study: 22356596
Drug: Supportive-experiential therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Supportive-experiential therapy (SET) group
Study: 20504210
Drug: Rasagiline monotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rasagiline monotherapy
Study: 20504210
Drug: Rasagiline therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rasagiline therapy
Study: 18561718
Drug: 500 mg
Normalized name: bran 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 500 mg of ciprofloxacin given 24 hours before return
Study: 15991508
Drug: Dexmedetomidine +
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexmedetomidine + 3 mg kg(‐1) lidocaine
Study: 15991508
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (3 mg kg(‐1) lidocaine diluted with saline)
Study: 6541533
Drug: High-dose dexamethasone
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose dexamethasone (DXM) (regimen A)
Study: 6541533
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of DXM and high doses of metoclopramide (MCP) (regimen B)
Study: 27694568
Drug: 60 mg
Normalized name: opium 60 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 60 mg iron and 400 μg folic acid
Study: 23867040
Drug: Functional electrical
Normalized name: methyl salicylate
DrugBank: Methyl salicylate (DB09543)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Functional electrical stimulation with mirror therapy (FES with MT)
Study: 23867040
Drug: Functional electrical
Normalized name: methyl salicylate
DrugBank: Methyl salicylate (DB09543)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Functional electrical stimulation without mirror therapy (FES without MT)
Study: 22314470
Drug: Oral nifedipine
Normalized name: Nifedipine
DrugBank: Nifedipine (DB01115)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral nifedipine (n=50)
Study: 3529351
Drug: Sequential female
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sequential female sex hormones and/or 1,25(OH)2D3, 0.25 microgram per day
Study: 29352461
Drug: Probiotic L.
Approvals — FDA: no, EMA: no, PMDA: no
Description: Probiotic L. reuteri lozenge (1 lozenge daily for 30 days)
Study: 29352461
Drug: Mechanical therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mechanical therapy alone (Control)
Study: 29352461
Drug: Probiotic L.
Approvals — FDA: no, EMA: no, PMDA: no
Description: Probiotic L. reuteri lozenge
Study: 18536619
Drug: Hib‐MenC‐TT booster
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hib‐MenC‐TT booster dose
Study: 15452683
Drug: Diazepam (15
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diazepam (15 mg/70 kg)
Study: 15452683
Drug: Flumazenil (1
Normalized name: Flumazenil (18-F)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Flumazenil (1 mg/70 kg, intravenously administered)
Study: 10064355
Drug: Creatine phosphate-enriched
Normalized name: Creatine phosphate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Creatine phosphate-enriched cardioplegic solution (group I)
Study: 10064355
Drug: Standard cardioplegic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard cardioplegic solution (group II)
Study: 1838923
Drug: perindopril (ACE
Approvals — FDA: no, EMA: no, PMDA: no
Description: perindopril (ACE inhibitor)
Study: 25768849
Drug: Istradefylline 20
Normalized name: istradefylline 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Istradefylline 20 mg/d (with possible adjustment to 40 mg/d)
Study: 25768849
Drug: Istradefylline 20
Normalized name: istradefylline 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Istradefylline 20 mg/d and 40 mg/d (previously taken in double-blind study)
Study: 19478653
Drug: Intramuscular oxygen-ozone
Normalized name: ozone
DrugBank: Ozone (DB12510)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intramuscular oxygen-ozone (O2O3) therapy
Study: 3307889
Drug: Simulated therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Simulated therapy (control)
Study: 16048250
Drug: Low glucose
Normalized name: ONE TOUCH LOW GLUCOSE CONTROL SOLN
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low glucose degradation product (GDP) dialysis solution
Study: 10073749
Drug: Omeprazole (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Omeprazole (20 mg single dose)
Study: 10073749
Drug: Omeprazole (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Omeprazole (20 mg daily for at least 1 week)
Study: 2043179
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of quinine sulfate plus theophylline ethylene diamine (CTED)
Study: 6756775
Drug: Laminaria and
Normalized name: Laminaria digitata preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Laminaria and continuous intravenous oxytocin infusion (Group C, 62 patients)
Study: 27784409
Drug: cb‐CBT‐I (computer-based
Approvals — FDA: no, EMA: no, PMDA: no
Description: cb‐CBT‐I (computer-based cognitive behavioral therapy for insomnia)
Study: 23614819
Drug: Intravenous lidocaine
Normalized name: Lidocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous lidocaine injection
Study: 17922738
Drug: Calcitriol therapy
Normalized name: Calcitriol
DrugBank: Calcitriol (DB00136)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Calcitriol therapy for 12 weeks
Study: 14994363
Drug: Warming therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Warming therapy (heating vest set to medium heat for 3 hours a day for 21 days)
Study: 11679149
Drug: HIV-1 MN
Normalized name: Mn 2+
Approvals — FDA: no, EMA: no, PMDA: no
Description: HIV-1 MN rgp160 ImmunoAG vaccine
Study: 11679149
Drug: Highly active
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Highly active antiretroviral therapy (HAART) (ritonavir, didanosine, and stavudine)
Study: 7524592
Drug: aprotinin (total
Approvals — FDA: no, EMA: no, PMDA: no
Description: aprotinin (total dose 2,000,000 kallikrein inhibiting units)
Study: 2908755
Drug: Balsalazide (BSZ)
DrugBank: Balsalazide (DB01014)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Balsalazide (BSZ) 1 g b.d. orally
Study: 2908755
Drug: Sulphasalazine (SASP)
Normalized name: Sulfasalazine
DrugBank: Sulfasalazine (DB00795)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sulphasalazine (SASP) 1 g b.d. orally
Study: 28460409
Drug: 10 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg/kg TA
Study: 28460409
Drug: 15 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 15 mg/kg TA
Study: 22968854
Drug: 375 mg
Normalized name: niacin 375 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 375 mg fosphenytoin sodium
Study: 22968854
Drug: 250 mg
Normalized name: rutin 250 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 250 mg phenytoin sodium
Study: 22968854
Drug: Fosphenytoin sodium
Normalized name: Fosphenytoin Sodium
DrugBank: Fosphenytoin (DB01320)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Fosphenytoin sodium (375, 563, and 750 mg)
Study: 10355071
Drug: Intravenous enalaprilat
Normalized name: Enalaprilat
DrugBank: Enalaprilat (DB09477)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous enalaprilat (initial dose: 2.5 mg; repetitive application of 2.5 mg every 30 min until a cumulative dose of 10 mg)
Study: 10355071
Drug: Sublingual nitroglycerine
Normalized name: nitroglycerin Sublingual Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sublingual nitroglycerine (initial dose: 0.8 mg; repetitive application of 0.8 mg every 10 min until a cumulative dose of 3.2 mg)
Study: 1790550
Drug: 50 mg
Normalized name: talc 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 mg of oral ubidecarenone daily
Study: 7214795
Drug: Beclomethasone dipropionate
Normalized name: Beclomethasone Dipropionate
DrugBank: Beclomethasone dipropionate (DB00394)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Beclomethasone dipropionate (BDP) 2 mg/day
Study: 7214795
Drug: Fluocortinbutyl (FCB)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluocortinbutyl (FCB) 40 mg/day
Study: 18250184
Drug: M vaccae
Normalized name: Mycobacterium vaccae
DrugBank: Mycobacterium vaccae (DB18449)
Approvals — FDA: no, EMA: no, PMDA: no
Description: M vaccae immunotherapy
Study: 12824212
Drug: Diluted smallpox
Normalized name: Smallpox vaccine
DrugBank: Smallpox (Vaccinia) Vaccine, Live (DB14711)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diluted smallpox vaccine (1:3.2)
Study: 12824212
Drug: Diluted smallpox
Normalized name: Smallpox vaccine
DrugBank: Smallpox (Vaccinia) Vaccine, Live (DB14711)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diluted smallpox vaccine (1:10)
Study: 12824212
Drug: Diluted smallpox
Normalized name: Smallpox vaccine
DrugBank: Smallpox (Vaccinia) Vaccine, Live (DB14711)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diluted smallpox vaccine (1:32)
Study: 12824212
Drug: Vaccinia‐naive participants
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vaccinia‐naive participants (undiluted vaccine)
Study: 1582788
Drug: Topical carteolol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical carteolol 1%
Study: 4015065
Drug: apalcillin 75
Approvals — FDA: no, EMA: no, PMDA: no
Description: apalcillin 75 mg/kg
Study: 4015065
Drug: apalcillin 150
Approvals — FDA: no, EMA: no, PMDA: no
Description: apalcillin 150 mg/kg
Study: 4015065
Drug: apalcillin 225
Approvals — FDA: no, EMA: no, PMDA: no
Description: apalcillin 225 mg/kg
Study: 4015065
Drug: apalcillin (all
Approvals — FDA: no, EMA: no, PMDA: no
Description: apalcillin (all doses)
Study: 26825021
Drug: 20-30 mg/24h
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20-30 mg/24h morphine SR
Study: 1441866
Drug: 10 ml
Normalized name: Vial Empty 10 mL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 ml bupivacaine 0.125% with 12.5 micrograms epinephrine (test dose)
Study: 1441866
Drug: 10 ml
Normalized name: Vial Empty 10 mL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 ml normal physiologic saline (control)
Study: 18459121
Drug: Group therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group therapy with hypnosis (and psychoeducation)
Study: 23417664
Drug: Multidimensional Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multidimensional Treatment Foster Care (MTFC)
Study: 12507634
Drug: Lutein (15
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lutein (15 mg, n = 5)
Study: 12507634
Drug: Alpha-tocopherol (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alpha-tocopherol (100 mg, n = 6)
Study: 1497931
Drug: Lidoflazine 1
Normalized name: lidoflazine 120 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lidoflazine 1 mg/kg intravenously over a period of 20 min before initiation of cardiopulmonary bypass
Study: 30596265
Drug: Expert moderated
Approvals — FDA: no, EMA: no, PMDA: no
Description: Expert moderated vaccine social media (VSM) website
Study: 30596265
Drug: Publicly available
Normalized name: povidone-iodine
DrugBank: Povidone-iodine (DB06812)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Publicly available parenting and vaccine-focused blogs and discussion forums
Study: 25952586
Drug: Traditional therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Traditional therapy group (N=23)
Study: 11952579
Drug: Glyceryl trinitrate
Normalized name: Glyceryl trinitrate
DrugBank: Nitroglycerin (DB00727)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Glyceryl trinitrate (GTN) ointment (0.2%)
Study: 11952579
Drug: Diltiazem hydrochloride
Normalized name: Diltiazem Hydrochloride
DrugBank: Diltiazem (DB00343)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Diltiazem hydrochloride (DTZ) cream (2%)
Study: 9458470
Drug: SPf66 (0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: SPf66 (0.5 mg or 1.0 mg)
Study: 9458470
Drug: SPf66 (high
Approvals — FDA: no, EMA: no, PMDA: no
Description: SPf66 (high dose Colombian vaccine)
Study: 3127188
Drug: Phenytoin sodium
Normalized name: Phenytoin Sodium
DrugBank: Phenytoin (DB00252)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Phenytoin sodium capsules 400 mg with enteral feedings (Ensure) at 100 ml/h for ten hours
Study: 3127188
Drug: Phenytoin sodium
Normalized name: Phenytoin Sodium
DrugBank: Phenytoin (DB00252)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Phenytoin sodium capsules 400 mg without enteral feedings
Study: 11564991
Drug: Valsartan 80
Normalized name: valsartan 80 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Valsartan 80 mg o.d. (or valsartan 80 mg + HCTZ 12.5 mg o.d. after 4 weeks if needed)
Study: 11564991
Drug: Amlodipine 5
Normalized name: amlodipine 5 MG
DrugBank: Amlodipine (DB00381)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Amlodipine 5 mg o.d. (or amlodipine 10 mg o.d. after 4 weeks if needed)